White & Case Advises CVC Capital Partners-Led Investment Consortium on Acquisition of Controlling Stake in Alvogen
Global law firm White & Case LLP has advised an investment consortium led by CVC Capital Partners, one of the world's leading private equity and investment advisory firms, and including Singapore-based investment company Temasek and Vatera Healthcare, on the acquisition of a controlling stake in Alvogen from Pamplona Capital Management.
Alvogen is an international, privately-owned pharmaceuticals company focused on developing, manufacturing and distributing generic, brand, over-the-counter brands and biosimilar products. It has commercial operations in 35 countries and 2,300 employees.
CVC Capital Partners and its co-investors will contribute significant experience and additional resources that will support Alvogen's ambition of becoming one of the world's leading generics players.
"The opportunity to represent such a prestigious consortium clearly plays to our strengths, showcasing the ability White & Case has to advise financial investors in acquiring companies with a global footprint," said London-based White & Case partner Ian Bagshaw, who co-led the Firm's deal team. "This was key to the delivery of a successful transaction."
The White & Case team which advised the consortium on its acquisition was led by partners Ian Bagshaw (London) and Oliver Brahmst (New York) and included partners Brian Smarsh (New York), Justin Wagstaff and Marcus Booth (both London) and associate Steven Hannah (London).
For more information please speak to your local media contact.